

MINUTES OF THE PHARMACEUTICAL MANAGEMENT AGENCY (PHARMAC)

OUT-OF-CYCLE BOARD MEETING HELD AUGUST 2022

The meeting was held by Zoom and started at 9.00am with the following attendees:

Board members

Steve Maharey	Chair
Anthony Jordan	Board member
Talia Anderson-Town	Board member
Elizabeth Zhu	Institute of Directors, Future Director

Pharmac staff in attendance

Sarah Fitt	Chief Executive
Carol Morris	Board Secretary
Lisa Williams	Director of Operations
Peter Alsop	Director of Engagement & Implementation
Michael Johnson	Director of Strategic Initiatives
Kathryn McInteer	Director Corporate Services
Trevor Simpson	Chief Advisor Māori
David Hughes	Chief Medical Officer

The Board Meeting started with a Karakia.

1. Directors-only Discussion

1.1 Glossary of Terms

1.2 Board Actions

The Board **noted** the Board Actions.

1.3 Board Annual Agenda 2022

The Board **noted** the Annual Agenda 2022.

1.4 Board and Committee Member Terms

The Board **noted** the Board and Committee Member terms.

1.5 Apologies

Claudia Wyss, Deputy Chair
Diana Siew, Board member

1.6 Rōpū update

The Board and Rōpū meeting planned for afternoon of 26 August was cancelled. The Board and Rōpū will look to reschedule a joint meeting with an external facilitator.

2. Record of Previous Meetings

2.1 Minutes of 29 July 2022 Board Meeting

The Board **resolved** to adopt the minutes of the 29 July 2022 Board meeting as being a true and correct record.

Talia Anderson-Town and Anthony Jordan

Carried

2.2 Minutes of the Health and Safety Committee held on 29 July 2022

The Board **noted** the minutes of the Health and Safety Committee Meeting held on 29 July 2022.

3. Interests Register

The Board:

noted the interests register.

4. Key items

4.1 Revised 2022/23 Statement of Performance Expectations

This paper presented the updated Pharmac 2022/23 Statement of Performance Expectations (SPE) for final review and Board approval.

The Board:

noted that the 2022/23 Statement of Performance Expectations was considered by the Board at its May meeting, before the Government response to the Pharmac Review was released on 1 June 2022

noted that changes reflecting Pharmac's Review response have been made to the 2022/23 Statement of Performance Expectations

approved the updated 2022/23 Statement of Performance Expectations

noted that following Board approval and any feedback from the Minister of Health, the 2022/23 Statement of Performance Expectations will be presented to the House of Representatives.

Approved subject to typographical changes.

Talia Anderson-Town and Anthony Jordan

Carried

4.2 Draft 2021/22 Annual Report

This paper presented an early draft of Pharmac's Annual Report 2021/22 for Board consideration and gave the Board the opportunity to provide initial thoughts and feedback as content is being developed and performance measures are finalised over coming months.

The Board will have a second opportunity to review the draft Annual Report 2021/22 at its meeting in October 2022.

The Board:

noted the progress on the draft of the Annual Report 2021/22

noted that we are seeking early Board feedback on the draft Annual Report, particularly in relation to content that the Board would like to see

noted that the draft Annual Report will next be considered by the Board in October and then for final approval in November following receipt of Audit NZ's 2021/22 management report.

A final draft will go to Audit NZ in October and will be taken to the Audit and Risk Committee in November, and subsequently to the Board for approval.

4.3 Update on Paediatric Cancer Pharmaceutical Treatment Funding

This paper provided the Board with an update on our review of rule 8.1b of the Pharmaceutical Schedule.

The Board:

noted that Pharmac staff have been reviewing the funding pathway for paediatric cancer treatments under [rule 8.1b](#) of the Pharmaceutical Schedule

noted that Pharmac has publicly committed to ensuring that all paediatric cancer treatments currently used continue to be available to current and future patients

noted that we intend to run a two-step public consultation process for the review of rule 8.1b of the Pharmaceutical Schedule

noted the first step would be the public release of a discussion paper in mid-September 2022

noted that the second step would be the release of a further consultation paper in late 2022, with options including staying with the status quo

noted that we are developing a robust communication and engagement plan to support the public consultation process.

4.4 COVID-19 Further supply of Paxlovid

Pharmac staff requested approval from the Board on an agreement amendment to secure further supply of nirmatrelvir with ritonavir (Paxlovid) for the treatment of COVID-19.

The Board:

Having regard to the decision-making framework set out in Pharmac's Operating Policies and Procedures, the Board:

resolved to approve the amendment to the supply agreement with Pfizer New Zealand Limited (Pfizer) for the supply of nirmatrelvir with ritonavir (Paxlovid)

Anthony Jordan and Talia Anderson-Town **Carried**

5. General Business

None noted.

The meeting closed at 11.30 am with a karakia.

The date for the next Board meeting is set for Friday, 30 September 2022.

Chair: _____

Date: _____